Do analysts rate VIRI or DARE?

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate DARE or SCLX?

Dare Bioscience currently has a consensus target price of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Dare Bioscience is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or SCLX more profitable?

Dare Bioscience has a net margin of -803.80% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -748.30% -38.75% Scilex -1,414.57% N/A -147.00%

Does the media refer more to DARE or SCLX?

In the previous week, Dare Bioscience had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Scilex. Dare Bioscience's average media sentiment score of -0.18 beat Scilex's score of -0.35 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GRCE or DARE?

In the previous week, Dare Bioscience had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VERU or DARE more profitable?

Veru has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Veru's return on equity of -47.58% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Dare Bioscience -803.80% -748.30% -38.75%

Does the media favor VERU or DARE?

In the previous week, Dare Bioscience had 1 more articles in the media than Veru. MarketBeat recorded 3 mentions for Dare Bioscience and 2 mentions for Veru. Veru's average media sentiment score of 0.34 beat Dare Bioscience's score of -0.18 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AGFY or DARE?

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is AGFY or DARE more profitable?

Agrify has a net margin of -424.11% compared to Dare Bioscience's net margin of -803.80%. Agrify's return on equity of -185.90% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Agrify -424.11% -185.90% -72.67% Dare Bioscience -803.80% -748.30% -38.75%

Dare Bioscience (DARE) Competitors

$0.71 -0.03 (-3.64%)

As of 09/3/2026 04:00 PM Eastern

Compare

DARE vs. VIRI, SCLX, GRCE, VERU, and AGFY

Should you buy Dare Bioscience stock or one of its competitors? Dare Bioscience's main competitors and comparable companies include Virios Therapeutics (VIRI), Scilex (SCLX), Grace Therapeutics (GRCE), Veru (VERU), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dare Bioscience compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

In the previous week, Dare Bioscience had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Dare Bioscience and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that Virios Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Dare Bioscience	Neutral

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Virios Therapeutics has higher earnings, but lower revenue than Dare Bioscience. Virios Therapeutics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A

Virios Therapeutics has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Virios Therapeutics' return on equity of -130.33% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Dare Bioscience	-803.80%	-748.30%	-38.75%

Summary

Virios Therapeutics beats Dare Bioscience on 8 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Scilex?

Dare Bioscience (NASDAQ:DARE) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Dare Bioscience has a net margin of -803.80% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Scilex	-1,414.57%	N/A	-147.00%

In the previous week, Dare Bioscience had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Scilex. Dare Bioscience's average media sentiment score of -0.18 beat Scilex's score of -0.35 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has higher earnings, but lower revenue than Scilex. Dare Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A
Scilex	$30.25M	1.48	-$358.73M	-$49.70	N/A

Dare Bioscience has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dare Bioscience currently has a consensus target price of $10.00, indicating a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Dare Bioscience is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Dare Bioscience beats Scilex on 10 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Grace Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Grace Therapeutics has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Grace Therapeutics' return on equity of -36.11% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Dare Bioscience	-803.80%	-748.30%	-38.75%

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 180.37%. Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Dare Bioscience had 2 more articles in the media than Grace Therapeutics. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grace Therapeutics has higher earnings, but lower revenue than Dare Bioscience. Grace Therapeutics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A

Summary

Dare Bioscience beats Grace Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Veru?

Veru (NASDAQ:VERU) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Veru has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Veru's return on equity of -47.58% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Dare Bioscience	-803.80%	-748.30%	-38.75%

47.2% of Veru shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Dare Bioscience had 1 more articles in the media than Veru. MarketBeat recorded 3 mentions for Dare Bioscience and 2 mentions for Veru. Veru's average media sentiment score of 0.34 beat Dare Bioscience's score of -0.18 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veru has a beta of -1.17, meaning that its stock price is 217% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Veru currently has a consensus target price of $24.50, suggesting a potential upside of 824.53%. Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 1,302.33%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Dare Bioscience is more favorable than Veru.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dare Bioscience has lower revenue, but higher earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.68	-$22.73M	-$0.69	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A

Summary

Veru and Dare Bioscience tied by winning 8 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to Agrify?

Agrify (NASDAQ:AGFY) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Agrify has a beta of 9.96, suggesting that its stock price is 896% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

6.0% of Agrify shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 2.2% of Agrify shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Agrify has a net margin of -424.11% compared to Dare Bioscience's net margin of -803.80%. Agrify's return on equity of -185.90% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Dare Bioscience	-803.80%	-748.30%	-38.75%

In the previous week, Dare Bioscience had 3 more articles in the media than Agrify. MarketBeat recorded 3 mentions for Dare Bioscience and 0 mentions for Agrify. Agrify's average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that Agrify is being referred to more favorably in the media.

Company	Overall Sentiment
Agrify	Neutral
Dare Bioscience	Neutral

Dare Bioscience has lower revenue, but higher earnings than Agrify. Agrify is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.92	-$41.75M	-$22.65	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.70	N/A

Summary

Dare Bioscience beats Agrify on 11 of the 16 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.56M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.02	787.27	273.28	25.38
Price / Sales	13.62	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-23.77	12.33	12.89	6.14
Net Income	-$13.40M	$2.82B	$3.47B	$349.01M
7 Day Performance	-2.98%	2.60%	0.61%	-0.27%
1 Month Performance	-46.98%	6.96%	5.73%	0.68%
1 Year Performance	-66.52%	9.48%	25.37%	14.84%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.1423 of 5 stars	$0.71 -3.6%	$10.00 +1,302.3%	-65.4%	$14.56M	$1.03M	N/A	30
VIRI Virios Therapeutics	N/A	$2.56 +2.8%	N/A	-48.4%	$49.30M	N/A	N/A	5
SCLX Scilex	0.7554 of 5 stars	$5.65 -0.2%	N/A	-72.0%	$47.99M	$31.61M	N/A	80	Analyst Upgrade
GRCE Grace Therapeutics	1.4563 of 5 stars	$2.20 +0.9%	$6.00 +172.7%	-27.9%	$46.29M	N/A	N/A	N/A	News Coverage Positive News
VERU Veru	2.7097 of 5 stars	$2.71 +4.6%	$24.50 +804.1%	-19.9%	$46.21M	N/A	N/A	230	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. VIRI, SCLX, GRCE, VERU, and AGFY

How does Dare Bioscience compare to Virios Therapeutics?

Summary

How does Dare Bioscience compare to Scilex?

Summary

How does Dare Bioscience compare to Grace Therapeutics?

Summary

How does Dare Bioscience compare to Veru?

Summary

How does Dare Bioscience compare to Agrify?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. VIRI, SCLX, GRCE, VERU, and AGFY

How does Dare Bioscience compare to Virios Therapeutics?

Does the media prefer VIRI or DARE?

Do institutionals and insiders have more ownership in VIRI or DARE?

Which has more risk & volatility, VIRI or DARE?

Do analysts rate VIRI or DARE?

Which has preferable earnings and valuation, VIRI or DARE?

Is VIRI or DARE more profitable?

Summary

How does Dare Bioscience compare to Scilex?

Is DARE or SCLX more profitable?

Does the media refer more to DARE or SCLX?

Which has higher earnings and valuation, DARE or SCLX?

Which has more risk and volatility, DARE or SCLX?

Do institutionals & insiders have more ownership in DARE or SCLX?

Do analysts rate DARE or SCLX?

Summary

How does Dare Bioscience compare to Grace Therapeutics?

Do institutionals and insiders hold more shares of GRCE or DARE?

Which has more volatility & risk, GRCE or DARE?

Is GRCE or DARE more profitable?

Do analysts prefer GRCE or DARE?

Does the media prefer GRCE or DARE?

Which has better earnings & valuation, GRCE or DARE?

Summary

How does Dare Bioscience compare to Veru?

Is VERU or DARE more profitable?

Do institutionals & insiders hold more shares of VERU or DARE?

Does the media favor VERU or DARE?

Which has more volatility and risk, VERU or DARE?

Do analysts prefer VERU or DARE?

Which has higher valuation & earnings, VERU or DARE?

Summary

How does Dare Bioscience compare to Agrify?

Do analysts recommend AGFY or DARE?

Which has more risk and volatility, AGFY or DARE?

Do insiders & institutionals believe in AGFY or DARE?

Is AGFY or DARE more profitable?

Does the media favor AGFY or DARE?

Which has stronger valuation & earnings, AGFY or DARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools